Skip to main content
. Author manuscript; available in PMC: 2010 Oct 20.
Published in final edited form as: HIV Clin Trials. 2009 Nov–Dec;10(6):343–355. doi: 10.1310/hct1006-343

Table 5. Baseline demographics by different arms.

Arm 1 (n = 86) Arm 2 (n = 114) Arm 3 (n = 33) Arm 4 (n = 70) p
Age, years
 Mean (SD) 39.2 (9.2) 36.4 (7.8) 40.5 (8.7) 37.7 (8.0) .44
 Min, Max 20, 64 21, 67 26, 61 19, 61
Gender .78
 Male 73 (85%) 91 (80%) 26 (79%) 56 (80%)
 Female 13 (15%) 23 (20%) 7 (21%) 14 (80%)
Race .71
 White 45 (52%) 60 (53%) 14 (42%) 36 (51%)
 Black 28 (33%) 38 (33%) 11 (33%) 26 (37%)
 Hispanic 10 (12%) 14 (13%) 7 (21%) 6 (9%)
 Others 3 (4%) 2 (1%) 1 (3%) 2 (3%)
IV drug use .41
 Never 81 (94%) 101 (89%) 30 (91%) 61 (87%)
 Currently 1 (1%) 0 0 0
 Previous 4 (5%) 13 (11%) 3 (9%) 9 (13%)
Education, years
 Mean (SD) 14.2 (2.8) 13.3 (2.3) 13.7 (2.1) 13.2 (2.6) .19
 Min, Max 9, 23 7, 18 9, 19 4, 19
CD4 count
 Mean (SD) 305.2 (324.1) 230.6 (191.0) 270.4 (190.4) 244.9 (225.7) .22
 Min, Max 0, 2594 3, 802 7, 818 3, 1005
log10, HIV-1 RNA
 Mean (SD) 4.81 (0.74) 4.89 (0.73) 4.86 (0.59) 4.89 (0.77) .86
 Min, Max 3.03, 6.63 2.70, 6.52 4.00, 6.19 3.05, 6.62

Note: Arm 1: randomized to EFV and continued EFV with long-term term data; Arm 2: randomized to EFV but do not have long term data on EFV; Arm 3: randomized to non-EFV and continued on non-EFV with long term data; Arm 4: randomized to non-EFV but do not have long term data on non-EFV. p value is overall test among four arms.